Fargo, North Dakota
Cancer biologic therapy trials in Fargo, ND
36 cancer biologic therapy studies are recruiting participants at sites in Fargo as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Fargo at a glance
- 36 studies are recruiting at a site in Fargo.
- By phase: Phase 1/2 (3), Phase 2 (13), Phase 2/3 (1), Phase 3 (19).
- By sponsor: government (13), university, hospital or other (12), industry (11).
- By research area: Lung Cancer (16), Lymphoma (11), Breast Cancer (6), Melanoma (2), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Fargo
Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT05564377 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0056)
- Registry record
- NCT06393374 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Essentia Health Cancer Center-South University Clinic
- Registry record
- NCT06058377 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Essentia Health Cancer Center-South University Clinic · Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT06876714 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Fargo, ND on ClinicalTrials.gov.
Lung cancer studies recruiting in Fargo
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Essentia Health Cancer Center-South University Clinic · Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT06498635 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Essentia Health Cancer Center-South University Clinic
- Registry record
- NCT07388524 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center ( Site 3236)
- Registry record
- NCT07513376 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT06096844 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057)
- Registry record
- NCT06312137 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Sanford Fargo Medical Center
- Registry record
- NCT06646276 · updated
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Health Roger Maris Cancer Center ( Site 0039)
- Registry record
- NCT07252739 · updated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center ( Site 0039)
- Registry record
- NCT04165070 · updated
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center ( Site 0039)
- Registry record
- NCT06731907 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- From 18 minutes
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT06031688 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Essentia Health Cancer Center-South University Clinic · Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT06616584 · updated
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT05624996 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Fargo, ND on ClinicalTrials.gov.
Melanoma studies recruiting in Fargo
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Essentia Health Cancer Center-South University Clinic · Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT05136196 · updated
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Call for Information (Investigational Site 0070)
- Registry record
- NCT02332668 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Fargo, ND on ClinicalTrials.gov.
Lymphoma studies recruiting in Fargo
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sanford Broadway Medical Center
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Essentia Health Cancer Center-South University Clinic
- Registry record
- NCT06337318 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Health Roger Maris Cancer Center ( Site 0189)
- Registry record
- NCT06717347 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sanford Broadway Medical Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sanford Broadway Medical Center
- Registry record
- NCT05675410 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Essentia Health Cancer Center-South University Clinic
- Registry record
- NCT06649812 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Essentia Health Cancer Center-South University Clinic · Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT05976763 · updated
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Phase 1/2
- From 6 months, up to 25 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003)
- Registry record
- NCT06395103 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sanford Broadway Medical Center
- Registry record
- NCT06124157 · updated
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Sanford Broadway Medical Center · Sanford Roger Maris Cancer Center
- Registry record
- NCT05633615 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Sanford Broadway Medical Center
- Registry record
- NCT03959085 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Fargo, ND on ClinicalTrials.gov.
Ask about studies near Fargo
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections